U.S. Markets close in 5 hrs 43 mins

Pacific Biosciences upgraded to Neutral from Underweight at JPMorgan

JPMorgan upgraded Pacific Biosciences to Neutral citing valuation and stronger system placements following the company's Q1 results. The firm has a $7 price target for shares.